We found evidence of ZIKV infection in amniotic epithelial cells and in fetal mesenchymal cells with affinity for perichondrium. Our observation indicates that ZIKV replicates in pluripotent (amniotic stem) cells involved in early-stage embryo development. The observation of prolonged viremia until day 21 in the patient is in concordance with the findings of Driggers et al. 3 and provides further data for consideration in the ongoing development of testing algorithms in pregnant women. These algorithms are currently based on the assumption that ZIKV viremia can be detected only up to 7 days.
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Cheyne-Stokes Respiration, Chemoreflex, and TicagrelorRelated Dyspnea
To the Editor: Dyspnea is a common side effect of the P2Y12-receptor antagonist ticagrelor in patients who receive this drug after an acute coronary syndrome. 1,2 Symptoms develop in a dose-dependent fashion and usually disappear on discontinuation of ticagrelor and with reductions in plasma levels of the drug.
1,2 The mechanism of this side effect, which is unrelated to negative effects on cardiac and pulmonary function, is unknown.
2
Here we describe the case of a patient (Patient 1) who was hospitalized for non-ST-segment elevation myocardial infarction. After the patient underwent complete revascularization for three-vessel coronary artery disease, double antiplatelet therapy with aspirin and ticagrelor was initiated. Within a few hours after the administration of ticagrelor, the patient began to report dyspnea, particularly at night and in the supine position, despite normal systolic and diastolic left ventricular function and normal pulmonary function. The results of the arterial blood gas analysis were normal, as were outcomes of pulmonary function as assessed by spirometry, which was performed in conformity with the American Thoracic Society-European Respiratory Society standards and included measures of slow vital capacity, forced vital capacity, and forced expiratory volume in 1 second; static lung volumes; and the diffusing capacity of the lung for carbon monoxide.
One month later, during a visit for persisting dyspnea, the patient was observed to have an abnormal pattern of periodic breathing, with alternating apneas and hyperventilation. Thus, 24-hour cardiorespiratory monitoring was performed. As shown in Figure 1A (top), this monitoring revealed the presence of CheyneStokes respiration (central apnea and hyperpnea), which occurred during both the night and the day. The rebreathing technique (i.e., a breathing circuit in which exhaled air is inhaled with or without absorption of carbon dioxide or oxygen) also showed increased chemosensitivity to hypercapnia (Fig. 1A , middle) and normal chemosensitivity to hypoxia. Immediately after the patient discontinued ticagrelor and switched to clopidogrel, the dyspnea attenuated and then disappeared. Serial evaluations of the patient's breathing pattern and chemosensitivity performed at 1 week and at 1 month after discontinuation of ticagrelor showed a progressive reduction, to normal values, of both the apnea-hypopnea index (AHI, the number of occurrences of apnea or hypopnea per hour) (Fig. 1B, top, and 1C, top) and chemosensitivity to hypercapnia (Fig. 1B , middle, and 1C, middle).
The same respiratory pattern was confirmed in three other patients who had normal cardiopulmonary function and who were screened for Cheyne-Stokes respiration 1 month after an acute coronary syndrome. In Patient 2, the diurnal AHI was 28 and the nocturnal AHI was 48. In Patient 3, the diurnal AHI was 41 and the nocturnal AHI 74, and in Patient 4, the diurnal AHI was 30 and the nocturnal AHI 58. In these three patients, ticagrelor was continued on the basis of a clinical decision, and in two patients, the follow-up confirmed the persistence of Cheyne-Stokes respiration. In Patient 2, the diurnal AHI after 1 week was 3 and the nocturnal AHI 35; in Patient 3, the diurnal AHI after 1 month was 13 and the nocturnal AHI 59. . Diurnal and nocturnal scores on the apnea-hypopnea index (AHI, the number of occurrences of apnea or hypopnea per hour) are shown. The patient also had increased chemosensitivity to carbon dioxide while receiving ticagrelor (Panel A, middle and bottom). After discontinuation of the drug, the amelioration of symptoms occurred with progressive disappearance of Cheyne-Stokes respiration (Panels B, top, and C, top) and a reduction in chemoreflex sensitivity to hypercapnia (Panels B, middle and bottom, and C, middle and bottom). AU denotes arbitrary units, HCVR hypercapnic ventilatory response, PetCO 2 partial pressure of end-tidal carbon dioxide, and SaO 2 arterial oxygen saturation. The P2Y12 receptor is expressed not only in platelets but also in other hematopoietic and nonhematopoietic cells, including microglia in the central nervous system, 4 with potential purinergic stimulation of the chemoreflex system. 
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